APC-300

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205814

CAS#: NONE

Description: APC-300 is a natural compound that, in pre-clinical studies, has been shown to not only inhibit the growth, but also stimulates the death of human prostate cancer cells. APC-300 is a small molecule signal transduction inhibitor that acts as an anti-inflammatory agent and blocks prostate cancer progression in in vivo models of the disease. In addition to prostate cancer, APC-300 has also demonstrated efficacy in disease models of human melanoma and pancreatic cancer. Adamis believes that APC-300 may have potential applications in the treatment of several tumor types. APC-300 is currently in preclinical development.


Price and Availability

Size
Price

Size
Price

Size
Price

APC-300, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

No image available

Theoretical Analysis

MedKoo Cat#: 205814
Name: APC-300
CAS#: NONE
Chemical Formula:
Exact Mass:
Molecular Weight:
Elemental Analysis:


Synonym: APC300; APC-300; APC 300

IUPAC/Chemical Name: NONE


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

 1: Manner H, Enderle MD, Pech O, May A, Plum N, Riemann JF, Ell C, Eickhoff A. Second-generation argon plasma coagulation: two-center experience with 600 patients. J Gastroenterol Hepatol. 2008 Jun;23(6):872-8. doi: 10.1111/j.1440-1746.2008.05437.x. PubMed PMID: 18565020.

2: Manner H, May A, Faerber M, Pech O, Plum N, Ell C. The tissue effect of second generation argon plasma coagulation (VIO APC) in comparison to standard APC and Nd:YAG laser in vitro. Acta Gastroenterol Belg. 2007 Oct-Dec;70(4):352-6. PubMed PMID: 18330091.

3: Dang BW, Zhang J. [The efficacy of endobronchial argon plasma coagulation in the management of intraluminal obstructive lesions of the central airway]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 May;30(5):330-3. Chinese. PubMed PMID: 17651635.

4: Nomura T, Miyashita M, Makino H, Maruyama H, Katsuta M, Kashiwabara M, Takahashi K, Sasajima K, Yamashita K, Tajiri T. Argon plasma coagulation for the treatment of superficial esophageal carcinoma. J Nippon Med Sch. 2007 Apr;74(2):163-7. PubMed PMID: 17507793.

5: Miyazawa T, Nawashiro H, Shima K, Bertalanffy H. Early experiences of haemostasis on brain tumour surgery with Argon Plasma Coagulation (APC). Acta Neurochir (Wien). 2000;142(11):1247-51. PubMed PMID: 11201639.

6: Roach SK, Kozarek RA, Raltz SL, Sumida SE. In vitro evaluation of integrity and sterilization of single-use argon beam plasma coagulation probes. Am J Gastroenterol. 1999 Jan;94(1):139-43. PubMed PMID: 9934744.

7: Katsuura Y, Aoki K, Tanabe H, Kiyoki M, Funatsu A. Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits. Thromb Res. 1994 Nov 15;76(4):353-62. PubMed PMID: 7871494.